IP Library Granted Patent US 8,980,920
Granted Patent B2
US 8,980,920 · App. 13/375,094 · Granted Mar 17, 2015

Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,920
App. No.
13/375,094
Granted
Mar 17, 2015
Kind
B2
Abstract

The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56.

Claims (24)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

A is

B is selected from:

wherein either one of the two available bonds of each depicted group can be connected to either of the two groups flanking B;

D is:

L 1 is a bond, —CH 2 —, —CH 2 —CH 2 —, —CH 2 —C(O)—, —NHCH 2 —, —NH, —C(O)—, —N(CH 3 )—, —CH═CH— or —C≡C—;

L 2 is a bond, —CH 2 —, —CH 2 —CH 2 —, —C≡C—, —NH, —C(O)— or —N(CH 3 )—, such that at least one of L 1 and L 2 is other than a bond;

R 1 is:

R 2 is:

each occurrence of R 5 is independently —C(O)—C(R 21 )—NHC(O)O-alkyl, —C(O)—C(alkyl)-NHC(O)N(R 20 ) 2 , —C(O)—C(R 20 )—N(R 20 ) 2 , —C(O)-alkyl, —C(O)O-alkyl or —C(O)—C(alkyl)-NHS(O) 2 -alkyl;

each occurrence of R 20 is independently H or —C 1 -C 4 alkyl; and

each occurrence of R 21 is independently phenyl or —C 1 -C 4 alkyl.

2. The compound of claim 1 , wherein A-R 1 and D-R 2 are each independently selected from

3. The compound of claim 2 , wherein B is:

wherein either one of the two available bonds of each depicted group can be connected to either of the two groups flanking B.

4. The compound of claim 2 , wherein each occurrence of R 5 is independently selected from:

5. The compound of claim 4 , wherein B is:

wherein either one of the two available bonds of each depicted group can be connected to either of the two groups flanking B.

6. The compound of claim 4 , wherein each occurrence of R 5 is

7. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Feb 21, 2014
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 032271/0082 →